Investors

Media

Welcome to the new Regeneron Newsroom. This newsroom is designed to provide members of the media with easy access to up-to-date information about the Company.

For an e-mail response to questions about Regeneron, please contact us at media@regeneron.com.



Upcoming Events

Nov 4, 2014
8:30 AM ET
Webcast Regeneron Pharmaceuticals Q3 2014 Earnings Conference Call


View all releases Recent Press Releases

Oct 20, 2014 Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis
Oct 17, 2014 EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
Oct 16, 2014 Regeneron Ranked Number One Biopharmaceutical Employer by Science Magazine for Third Consecutive Year
Oct 16, 2014 Regeneron Genetics Center Fully Operational, Announces New Collaborations and Key Appointments
Oct 15, 2014 Regeneron to Report Third Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2014
Oct 6, 2014 EYLEA® (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO)
Sep 30, 2014 Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps
Sep 22, 2014 Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization (CNV) in Japan
Sep 16, 2014 EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema
Sep 4, 2014 Regeneron Announces Submission of Application for EYLEA® (aflibercept) Injection in Japan for Macular Edema Following Branch Retinal Vein Occlusion


Close
Form content here please :)